Clinical Trial Results:
A Phase 3, Randomized, Comparative, Multicenter Observer-Blind Study Evaluating the Safety and Immunogenicity of Novartis rMenB+OMV NZ Vaccine Formulated with Outer Membrane Vesicle (OMV) Manufactured at Two Different Sites, in Healthy Adolescents Aged 11-17 Years
Due to a system error, the data reported in v1 is not correct and has been removed from public view.
Summary
|
|
EudraCT number |
2014-004476-30 |
Trial protocol |
Outside EU/EEA |
Global end of trial date |
01 Dec 2011
|
Results information
|
|
Results version number |
v2(current) |
This version publication date |
03 Jun 2016
|
First version publication date |
26 Dec 2014
|
Other versions |
v1 (removed from public view) |
Version creation reason |
Trial Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
|
|||
Trial identification
|
|||
Sponsor protocol code |
V72_41
|
||
Additional study identifiers
|
|||
ISRCTN number |
- | ||
US NCT number |
NCT01423084 | ||
WHO universal trial number (UTN) |
- | ||
Sponsors
|
|||
Sponsor organisation name |
Novartis Vaccines and Diagnostics SRL
|
||
Sponsor organisation address |
Via Fiorentina 1, Siena, Italy, 53100
|
||
Public contact |
Posting Director, Novartis Vaccines and Diagnostics SRL, RegistryContactVaccinesUS@novartis.com
|
||
Scientific contact |
Posting Director, Novartis Vaccines and Diagnostics SRL, RegistryContactVaccinesUS@novartis.com
|
||
Paediatric regulatory details
|
|||
Is trial part of an agreed paediatric investigation plan (PIP) |
No
|
||
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Results analysis stage
|
|||
Analysis stage |
Final
|
||
Date of interim/final analysis |
30 Mar 2012
|
||
Is this the analysis of the primary completion data? |
No
|
||
Global end of trial reached? |
Yes
|
||
Global end of trial date |
01 Dec 2011
|
||
Was the trial ended prematurely? |
No
|
||
General information about the trial
|
|||
Main objective of the trial |
To demonstrate the equivalence of rMenB+OMV NZ lot 1 to rMenB+OMV NZ lot 2 when administered to adolescents, as measured by human serum bactericidal activity (hSBA) geometric mean titers (GMTs) against 3 N. meningitidis serogroup B reference strains (H44/76, 5/99, and NZ98/254) and as measured by Enzymelinked immunosorbent assay (ELISA) geometric mean concentrations (GMCs) against vaccine antigen 287-953, approximately 30 days after a primary vaccination course of two doses administered one month apart.
|
||
Protection of trial subjects |
This clinical study was designed, conducted and reported in accordance with the International Conference on Harmonization (ICH) Harmonized Tripartite Guidelines for GCP, with applicable local regulations (including European Directive 2001/20/EC, US Code of Federal Regulations Title 21, and Japanese Ministry of Health, Labor, and Welfare), with the ethical principles laid down in the Declaration of Helsinki, and with the applicable regulatory requirement(s) for the country in which the trial was conducted. Specifically, this trial was conducted under a protocol reviewed and approved by an EC; the trial was conducted by scientifically and medically qualified persons; the benefits of the study are in percentage to the risks; the rights and welfare of the subjects were respected; the physicians conducting the trial did not find the hazards to outweigh the potential benefits; each subject, or where applicable, each subject's legally acceptable representative(s) gave his or her written informed consent before any protocol-driven tests or evaluations were performed. A copy of the ICH GCP guidelines and of the Declaration of Helsinki was included in the investigator's study file.
|
||
Background therapy |
- | ||
Evidence for comparator |
- | ||
Actual start date of recruitment |
30 Aug 2011
|
||
Long term follow-up planned |
No
|
||
Independent data monitoring committee (IDMC) involvement? |
No
|
||
Population of trial subjects
|
|||
Number of subjects enrolled per country |
|||
Country: Number of subjects enrolled |
Australia: 75
|
||
Country: Number of subjects enrolled |
Canada: 269
|
||
Worldwide total number of subjects |
344
|
||
EEA total number of subjects |
0
|
||
Number of subjects enrolled per age group |
|||
In utero |
0
|
||
Preterm newborn - gestational age < 37 wk |
0
|
||
Newborns (0-27 days) |
0
|
||
Infants and toddlers (28 days-23 months) |
0
|
||
Children (2-11 years) |
48
|
||
Adolescents (12-17 years) |
296
|
||
Adults (18-64 years) |
0
|
||
From 65 to 84 years |
0
|
||
85 years and over |
0
|
|
|||||||||||||||||||
Recruitment
|
|||||||||||||||||||
Recruitment details |
Subjects were recruited from 7 centres in Canada and 6 in Australia | ||||||||||||||||||
Pre-assignment
|
|||||||||||||||||||
Screening details |
All subjects were enrolled in the trial | ||||||||||||||||||
Period 1
|
|||||||||||||||||||
Period 1 title |
Overall trial (overall period)
|
||||||||||||||||||
Is this the baseline period? |
Yes | ||||||||||||||||||
Allocation method |
Randomised - controlled
|
||||||||||||||||||
Blinding used |
Double blind | ||||||||||||||||||
Roles blinded |
Investigator, Monitor, Data analyst, Carer, Assessor, Subject | ||||||||||||||||||
Arms
|
|||||||||||||||||||
Are arms mutually exclusive |
Yes
|
||||||||||||||||||
Arm title
|
4CMenB_Rosia | ||||||||||||||||||
Arm description |
Subjects received two doses of rMenB+OMV NZ vaccine from lot 1 manufactured at Rosia facility. | ||||||||||||||||||
Arm type |
Experimental | ||||||||||||||||||
Investigational medicinal product name |
rMenB+OMV NZ
|
||||||||||||||||||
Investigational medicinal product code |
|||||||||||||||||||
Other name |
|||||||||||||||||||
Pharmaceutical forms |
Suspension for injection
|
||||||||||||||||||
Routes of administration |
Intramuscular use
|
||||||||||||||||||
Dosage and administration details |
Subjects received two injections of 0.5 mL dose administered intra-muscularly (IM) into the deltoid area.
|
||||||||||||||||||
Arm title
|
4CMenB_Siena | ||||||||||||||||||
Arm description |
Subjects received two doses of rMenB+OMV NZ vaccinations from lot 2 manufactured at Siena facility. | ||||||||||||||||||
Arm type |
Experimental | ||||||||||||||||||
Investigational medicinal product name |
rMenB+OMV NZ
|
||||||||||||||||||
Investigational medicinal product code |
|||||||||||||||||||
Other name |
|||||||||||||||||||
Pharmaceutical forms |
Suspension for injection
|
||||||||||||||||||
Routes of administration |
Intramuscular use
|
||||||||||||||||||
Dosage and administration details |
Subjects received two injections of 0.5 mL dose administered intra-muscularly (IM) into the deltoid area.
|
||||||||||||||||||
|
|
|||||||||||||||||||||||||||||||||||||||||||||
Baseline characteristics reporting groups
|
|||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
4CMenB_Rosia
|
||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Subjects received two doses of rMenB+OMV NZ vaccine from lot 1 manufactured at Rosia facility. | ||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
4CMenB_Siena
|
||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Subjects received two doses of rMenB+OMV NZ vaccinations from lot 2 manufactured at Siena facility. | ||||||||||||||||||||||||||||||||||||||||||||
|
|
|||
End points reporting groups
|
|||
Reporting group title |
4CMenB_Rosia
|
||
Reporting group description |
Subjects received two doses of rMenB+OMV NZ vaccine from lot 1 manufactured at Rosia facility. | ||
Reporting group title |
4CMenB_Siena
|
||
Reporting group description |
Subjects received two doses of rMenB+OMV NZ vaccinations from lot 2 manufactured at Siena facility. | ||
Subject analysis set title |
All Enrolled Set
|
||
Subject analysis set type |
Intention-to-treat | ||
Subject analysis set description |
All subjects who have signed an informed consent, undergone screening procedure(s) and were randomized.
|
||
Subject analysis set title |
All Exposed Set
|
||
Subject analysis set type |
Safety analysis | ||
Subject analysis set description |
All enrolled subjects who actually received a study vaccination.
|
||
Subject analysis set title |
Safety Set
|
||
Subject analysis set type |
Safety analysis | ||
Subject analysis set description |
All subjects in the Exposed population who provided post vaccination safety data
|
||
Subject analysis set title |
Per Protocol Set
|
||
Subject analysis set type |
Per protocol | ||
Subject analysis set description |
All subjects in the Enrolled Set who correctly received the vaccine, provided evaluable serum samples at the relevant time points and had no major protocol violation as defined prior to un-blinding.
|
|
||||||||||||||||||||||
End point title |
1) Human Serum Bactericidal Activity (hSBA) Geometric Mean Titers (GMTs) against 3 Neisseria.meningitidis (N. meningitidis) serogroup B reference strains. | |||||||||||||||||||||
End point description |
Two different lots of rMenB+OMV NZ are evaluated in terms of hSBA GMTs against 3 different strains of serogroup B N. meningitidis antigens.
|
|||||||||||||||||||||
End point type |
Primary
|
|||||||||||||||||||||
End point timeframe |
Day 61
|
|||||||||||||||||||||
|
||||||||||||||||||||||
Notes [1] - Analysis was done on the Per Protocol Set. [2] - Analysis was done on the Per Protocol Set. For strain 5/99, N=152 Stat. Analysis N=299 |
||||||||||||||||||||||
Statistical analysis title |
Equivalence of 2 differents lots of rMenB+OMV NZ | |||||||||||||||||||||
Statistical analysis description |
Equivalence of 2 differents lots of rMenB+OMV NZ in terms of hSBA GMTs against H44/76 strain
|
|||||||||||||||||||||
Comparison groups |
4CMenB_Rosia v 4CMenB_Siena
|
|||||||||||||||||||||
Number of subjects included in analysis |
298
|
|||||||||||||||||||||
Analysis specification |
Pre-specified
|
|||||||||||||||||||||
Analysis type |
equivalence [3] | |||||||||||||||||||||
Method |
||||||||||||||||||||||
Parameter type |
between groups ratio | |||||||||||||||||||||
Point estimate |
1
|
|||||||||||||||||||||
Confidence interval |
||||||||||||||||||||||
level |
95% | |||||||||||||||||||||
sides |
2-sided
|
|||||||||||||||||||||
lower limit |
0.82 | |||||||||||||||||||||
upper limit |
1.23 | |||||||||||||||||||||
Notes [3] - Two different lots of rMenB+OMV NZ are to be considered equivalent in terms of hSBA GMTs against H44/76 strain if t the two sided 95% Confidence Interval (CI) of the between groups GMTs ratio at day 31 (ie, one month after the second vaccination ) does not exceed the range 0.5 (lower limit) - 2.0 (higher limit). |
||||||||||||||||||||||
Statistical analysis title |
Equivalence of 2 differents lots of rMenB+OMV NZ | |||||||||||||||||||||
Statistical analysis description |
Equivalence of 2 differents lots of rMenB+OMV NZ in terms of hSBA GMTs against NZ98/254 strain
|
|||||||||||||||||||||
Comparison groups |
4CMenB_Rosia v 4CMenB_Siena
|
|||||||||||||||||||||
Number of subjects included in analysis |
298
|
|||||||||||||||||||||
Analysis specification |
Pre-specified
|
|||||||||||||||||||||
Analysis type |
equivalence [4] | |||||||||||||||||||||
Method |
||||||||||||||||||||||
Parameter type |
between groups ratio | |||||||||||||||||||||
Point estimate |
0.81
|
|||||||||||||||||||||
Confidence interval |
||||||||||||||||||||||
level |
95% | |||||||||||||||||||||
sides |
2-sided
|
|||||||||||||||||||||
lower limit |
0.6 | |||||||||||||||||||||
upper limit |
1.09 | |||||||||||||||||||||
Notes [4] - Two different lots of rMenB+OMV NZ are to be considered equivalent in terms of hSBA GMTs against NZ 98/254 strain if t the two sided 95% Confidence Interval (CI) of the between groups GMTs ratio at day 31 (ie, one month after the second vaccination ) does not exceed the range 0.5 (lower limit) - 2.0 (higher limit). |
||||||||||||||||||||||
Statistical analysis title |
Equivalence of 2 differents lots of rMenB+OMV NZ | |||||||||||||||||||||
Statistical analysis description |
Equivalence of 2 differents lots of rMenB+OMV NZ in terms of hSBA GMTs against 5/99 strain
|
|||||||||||||||||||||
Comparison groups |
4CMenB_Rosia v 4CMenB_Siena
|
|||||||||||||||||||||
Number of subjects included in analysis |
298
|
|||||||||||||||||||||
Analysis specification |
Pre-specified
|
|||||||||||||||||||||
Analysis type |
equivalence [5] | |||||||||||||||||||||
Method |
||||||||||||||||||||||
Parameter type |
between groups ratio | |||||||||||||||||||||
Point estimate |
0.92
|
|||||||||||||||||||||
Confidence interval |
||||||||||||||||||||||
level |
95% | |||||||||||||||||||||
sides |
2-sided
|
|||||||||||||||||||||
lower limit |
0.77 | |||||||||||||||||||||
upper limit |
1.1 | |||||||||||||||||||||
Notes [5] - Two different lots of rMenB+OMV NZ are to be considered equivalent in terms of hSBA GMTs against 5/99 strain if the two sided 95% Confidence Interval (CI) of the between groups GMTs ratio at day 31 (ie, one month after the second vaccination ) does not exceed the range 0.5 (lower limit) - 2.0 (higher limit). |
|
|||||||||||||
End point title |
2) Enzyme-linked immunosorbent assay (ELISA) geometric mean concentrations (GMCs) against vaccine antigen 287-953 | ||||||||||||
End point description |
The immune response of two different lots of rMenB+OMV NZ is evaluated in terms of ELISA GMCs against vaccine antigen 287-953.
|
||||||||||||
End point type |
Primary
|
||||||||||||
End point timeframe |
Day 61
|
||||||||||||
|
|||||||||||||
Notes [6] - Analysis was done on the Per Protocol Set. [7] - Analysis was done on the Per Protocol Set. |
|||||||||||||
Statistical analysis title |
Equivalence in terms of hSBA GMTs | ||||||||||||
Statistical analysis description |
Equivalence of 2 differents lots of rMenB+OMV NZ in terms of ELISA GMCs
|
||||||||||||
Comparison groups |
4CMenB_Rosia v 4CMenB_Siena
|
||||||||||||
Number of subjects included in analysis |
299
|
||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||
Analysis type |
equivalence [8] | ||||||||||||
Method |
|||||||||||||
Parameter type |
between groups ratio | ||||||||||||
Point estimate |
0.83
|
||||||||||||
Confidence interval |
|||||||||||||
level |
95% | ||||||||||||
sides |
2-sided
|
||||||||||||
lower limit |
0.67 | ||||||||||||
upper limit |
1.02 | ||||||||||||
Notes [8] - Two different lots of rMenB+OMV NZ are to be considered equivalent in terms of ELISA GMCs against vaccine antigen 287-953 if t the two sided 95% Confidence Interval (CI) of the between groups GMTs ratio at day 31 (ie, one month after the second vaccination ) does not exceed the range 0.5 (lower limit) - 2.0 (higher limit). |
|
||||||||||||||||||||||
End point title |
3) Percentage of Subjects with hSBA ≥1:5 against each of N. meningitidis serogroup B test strains. | |||||||||||||||||||||
End point description |
The immune response of two different lots of rMenB+OMV NZ against each of N. meningitidis serogroup B test strains is evaluated in terms of percentages of subjects with hSBA ≥1:5.
|
|||||||||||||||||||||
End point type |
Secondary
|
|||||||||||||||||||||
End point timeframe |
Day 61
|
|||||||||||||||||||||
|
||||||||||||||||||||||
Notes [9] - Analysis was done on the Per Protocol Set. [10] - Analysis was done on the Per Protocol Set |
||||||||||||||||||||||
No statistical analyses for this end point |
|
||||||||||||||||||||||
End point title |
4) Geometric Mean Ratio (GMR) of GMTs against each of N. meningitidis serogroup B reference strains. | |||||||||||||||||||||
End point description |
The immune response of two different lots of rMenB+OMV NZ against each of N. meningitidis serogroup B test strains is evaluated in terms of GMR between GMTs (1month after 2nd vaccination vs baseline).
|
|||||||||||||||||||||
End point type |
Secondary
|
|||||||||||||||||||||
End point timeframe |
Day 61
|
|||||||||||||||||||||
|
||||||||||||||||||||||
Notes [11] - Analysis was done on the Per Protocol Set. [12] - Analysis was done on the Per Protocol Set. |
||||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||
End point title |
5) GMR of ELISA GMCs against antigen 287-953 | ||||||||||||
End point description |
The immune response of two different lots of rMenB+OMV NZ against antigen 287-953 is evaluated in terms of GMRs between ELISA GMCs (day 61 vs baseline).
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
Day 61
|
||||||||||||
|
|||||||||||||
Notes [13] - Analysis was done on the Per Protocol Set. [14] - Analysis was done on the Per Protocol Set. |
|||||||||||||
No statistical analyses for this end point |
|
||||||||||||||||||||||
End point title |
6) hSBA GMT against 3 N. meningitidis serogroup B reference strains at day 45. | |||||||||||||||||||||
End point description |
The immunogenicity of two different lots of rMenB+OMV NZ is evaluated in terms of hSBA GMT against 3 N. Meningitidis serogroup B reference strains at two weeks after last vaccination.
|
|||||||||||||||||||||
End point type |
Secondary
|
|||||||||||||||||||||
End point timeframe |
Day 45
|
|||||||||||||||||||||
|
||||||||||||||||||||||
Notes [15] - Analysis was done on the PPS, immunogenicity subset. [16] - Analysis was done on the PPS, immunogenicity subset. |
||||||||||||||||||||||
No statistical analyses for this end point |
|
||||||||||||||||||||||
End point title |
7) GMRs of GMT against 3 N. meningitidis serogroup B reference strains at day 45. | |||||||||||||||||||||
End point description |
The immunogenicity of two different lots of rMenB+OMV NZ is evaluated in terms of GMRs of GMT against 3 N. meningitidis serogroup B reference strains at two weeks after last vaccination.
|
|||||||||||||||||||||
End point type |
Secondary
|
|||||||||||||||||||||
End point timeframe |
Day 45
|
|||||||||||||||||||||
|
||||||||||||||||||||||
Notes [17] - Analysis was done on the PPS, immunogenicity subset. [18] - Analysis was done on the PPS, immunogenicity subset. |
||||||||||||||||||||||
No statistical analyses for this end point |
|
||||||||||||||||||||||
End point title |
8) Percentage of Subjects with hSBA ≥1:5 against each of N. meningitidis serogroup B reference strains at day 45. | |||||||||||||||||||||
End point description |
The immune response of two different lots of rMenB+OMV NZ against each of N. Meningitidis serogroup B reference strains is evaluated in terms of percentages of subjects with hSBA ≥1:5 two weeks after the last vaccination.
|
|||||||||||||||||||||
End point type |
Secondary
|
|||||||||||||||||||||
End point timeframe |
Day 45
|
|||||||||||||||||||||
|
||||||||||||||||||||||
Notes [19] - Analysis was done on the PPS, immunogenicity subset. [20] - Analysis was done on the PPS, immunogenicity subset. |
||||||||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||
End point title |
9) ELISA GMCs against vaccine antigen 287-953 at day 45. | ||||||||||||
End point description |
The immune response of two different lots of rMenB+OMV NZ is evaluated in terms of ELISA GMCs against vaccine antigen 287-953.
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
Day 45
|
||||||||||||
|
|||||||||||||
Notes [21] - Analysis was done on the PPS, immunogenicity subset. [22] - Analysis was done on the PPS, immunogenicity subset. |
|||||||||||||
No statistical analyses for this end point |
|
|||||||||||||
End point title |
10) GMR of ELISA GMCs against antigen 287-953 at day 45. | ||||||||||||
End point description |
The immune response of two different lots of rMenB+OMV NZ against antigen 287-953 is evaluated in terms of GMRs between ELISA GMCs (day45 vs baseline).
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
Day 45
|
||||||||||||
|
|||||||||||||
Notes [23] - Analysis was done on the PPS, immunogenicity subset. [24] - Analysis was done on the PPS, immunogenicity subset. |
|||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||
End point title |
11) Number of subjects reporting solicited local and systemic Adverse Events (AEs) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
End point description |
Number of subjects reporting solicited local and systemic Adverse Events and other indicators of reactogenicity after any vaccination.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||
End point timeframe |
From day 1 to day 7 after any vaccination.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||
Notes [25] - Analysis was done on the Safety set. [26] - Analysis was done on the Safety set. |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||
No statistical analyses for this end point |
|
||||||||||
End point title |
12) Number of subjects reporting Unsolicited AEs | |||||||||
End point description |
Number of subjects reporting any Unsolicited AEs after any vaccination.
|
|||||||||
End point type |
Secondary
|
|||||||||
End point timeframe |
From day 1 to day 7 after any vaccination .
|
|||||||||
|
||||||||||
Notes [27] - Analysis was done on the Safety set. [28] - Analysis was done on the Safety set. |
||||||||||
No statistical analyses for this end point |
|
||||||||||||||||
End point title |
13) Number of subjects reporting SAEs and AE leading to withdrawal | |||||||||||||||
End point description |
Number of subjects any Serious AEs (SAEs), medically attended AEs and AEs that result in a subject’s withdrawal from the study after any vaccination.
|
|||||||||||||||
End point type |
Secondary
|
|||||||||||||||
End point timeframe |
Throughout the entire study period.
|
|||||||||||||||
|
||||||||||||||||
Notes [29] - Analysis was done on the Safety set. [30] - Analysis was done on the Safety set. |
||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Adverse events information
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Timeframe for reporting adverse events |
SAEs were collected from day 1 through study termination, other AEs were collected from day 1 to 7 after vaccination.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Adverse event reporting additional description |
Solicited adverse events were collected through systematic assessment, unsolicited were collected through non-systematic assessment. Analysis was done on the Safety set.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Assessment type |
Non-systematic | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary used for adverse event reporting
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary name |
MedDRA | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary version |
14.1
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting groups
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
4CMenB_Siena
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Subjects received two doses of rMenB+OMV NZ vaccinations from lot 2 manufactured at Siena facility. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
4CMenB_Rosia
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Subjects received two doses of rMenB+OMV NZ vaccine from lot 1 manufactured at Rosia facility. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Frequency threshold for reporting non-serious adverse events: 5% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||
Substantial protocol amendments (globally) |
|||
Were there any global substantial amendments to the protocol? No | |||
Interruptions (globally) |
|||
Were there any global interruptions to the trial? No | |||
Limitations and caveats |
|||
Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data. | |||
None reported |